Conquering hypertension in Vietnam-solutions at grassroots level: study protocol of a cluster randomized controlled trial by Ha, Duc A. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Population and Quantitative Health Sciences 
Publications Population and Quantitative Health Sciences 
2020-11-27 
Conquering hypertension in Vietnam-solutions at grassroots level: 
study protocol of a cluster randomized controlled trial 
Duc A. Ha 
Ministry of Health 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/qhs_pp 
 Part of the Cardiovascular Diseases Commons, Clinical Trials Commons, Community Health and 
Preventive Medicine Commons, Epidemiology Commons, Health Services Research Commons, 
International Public Health Commons, and the Preventive Medicine Commons 
Repository Citation 
Ha DA, Tran OT, Nguyen HL, Chiriboga G, Goldberg RJ, Phan VH, Nguyen CT, Nguyen GH, Pham HV, Nguyen 
TT, Le TT, Allison JJ. (2020). Conquering hypertension in Vietnam-solutions at grassroots level: study 
protocol of a cluster randomized controlled trial. Population and Quantitative Health Sciences 
Publications. https://doi.org/10.1186/s13063-020-04917-8. Retrieved from 
https://escholarship.umassmed.edu/qhs_pp/1389 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Population and 
Quantitative Health Sciences Publications by an authorized administrator of eScholarship@UMMS. For more 
information, please contact Lisa.Palmer@umassmed.edu. 
STUDY PROTOCOL Open Access
Conquering hypertension in
Vietnam—solutions at grassroots level:
study protocol of a cluster randomized
controlled trial
Duc A. Ha1,2†, Oanh T. Tran2†, Hoa L. Nguyen3*† , Germán Chiriboga3, Robert J. Goldberg3, Van H. Phan2,
Cuc T. Nguyen2, Giang H. Nguyen2, Hien V. Pham2, Thang T. Nguyen2, Thanh T. Le4,5 and Jeroan J. Allison3
Abstract
Background: Vietnam has been experiencing an epidemiologic transition to that of a lower-middle income
country with an increasing prevalence of non-communicable diseases. The key risk factors for cardiovascular disease
(CVD) are either on the rise or at alarming levels in Vietnam, particularly hypertension (HTN). Inasmuch, the burden
of CVD will continue to increase in the Vietnamese population unless effective prevention and control measures are
put in place. The objectives of the proposed project are to evaluate the implementation and effectiveness of two
multi-faceted community and clinic-based strategies on the control of elevated blood pressure (BP) among adults
in Vietnam via a cluster randomized trial design.
Methods: Sixteen communities will be randomized to either an intervention (8 communities) or a comparison
group (8 communities). Eligible and consenting adult study participants with HTN (n = 680) will be assigned to
intervention/comparison status based on the community in which they reside. Both comparison and intervention
groups will receive a multi-level intervention modeled after the Vietnam National Hypertension Program including
education and practice change modules for health care providers, accessible reading materials for patients, and a
multi-media community awareness program.
In addition, the intervention group only will receive three carefully selected enhancements integrated into routine
clinical care: (1) expanded community health worker services, (2) home BP self-monitoring, and (3) a “storytelling
intervention,” which consists of interactive, literacy-appropriate, and culturally sensitive multi-media storytelling
modules for motivating behavior change through the power of patients speaking in their own voices. The
storytelling intervention will be delivered by DVDs with serial installments at baseline and at 3, 6, and 9 months
after trial enrollment. Changes in BP will be assessed in both groups at several follow-up time points.
Implementation outcomes will be assessed as well.
(Continued on next page)
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Discussion: Results from this full-scale trial will provide health policymakers with practical evidence on how to
combat a key risk factor for CVD using a feasible, sustainable, and cost-effective intervention that could be used as
a national program for controlling HTN in Vietnam.
Trial registration: ClinicalTrials.gov NCT03590691. Registered on July 17, 2018. Protocol version: 6. Date: August 15,
2019.
Keywords: Hypertension, Self-monitoring blood pressure, Storytelling, Trial, Vietnam
Background
Epidemiologic transition in Vietnam, cardiovascular
disease, and hypertension
Vietnam is undergoing an epidemiological transition
with the morbidity and mortality from non-
communicable diseases having risen rapidly over the last
several decades [1, 2]. This transition can be attributed
to changes in population size, socio-demographic char-
acteristics, and increases in life expectancy [1–4]. Car-
diovascular disease (CVD) is now the leading cause of
death in Vietnam, accounting for 30% of all deaths an-
nually in 2010 [5]. Major risk factors for CVD including
hypertension, diabetes, unhealthy dietary practices, and
overweight/obesity are either on the rise or at alarming
levels in Vietnam [2, 6, 7]. National data showed that the
prevalence of hypertension (HTN) was more than 40%
for those 50–69 years old and the general population
consumed high levels of sodium in their diet in 2016 [7].
Although antihypertensive medications are off-patent,
widely available across the country, and are covered by
public health insurance (more than 80% of Vietnamese
have health insurance), the awareness and management
of hypertension are far from optimal [8]; this is due to
many factors including lack of regular screening and pa-
tient self-management strategies (e.g., medication adher-
ence, lifestyle modifications). Inasmuch, the burden of
CVD will continue to increase in the Vietnamese popu-
lation unless effective prevention and control measures
are put in place.
The health care system in Vietnam is organized into
four levels, which include the central, provincial, district,
and commune (community) level. The lowest level in-
cludes the community health centers (CHCs), which are
responsible for providing primary health care and out-
patient services, including implementation of national
health programs. There is typically one CHC per com-
munity, and at each CHC, there are approximately 10–
15 community health workers (CHWs). These individ-
uals are “natural helpers” without medical degrees who
serve as health advocates for their community [9], edu-
cators, and problem-solvers, and they provide valuable
linkages to available community resources [10]. Recent
studies have documented the positive role of CHWs in
improving HTN control through better home
monitoring, appointment keeping, medication adher-
ence, and health care use [11–13]. CHWs are present in
our partnering rural clinics and were an integral part of
our previous work [14–16].
Between 2014 and 2016, a feasibility cluster trial of a
storytelling intervention was conducted in Hung Yen
province, Vietnam, by members of the study team [14–
16]. The study included 160 patients with HTN with a
mean age of 66 years and 54% were men. Between base-
line enrollment and the 3-month follow-up, systolic
blood pressure (BP) declined by 8.2 mmHg (95% CI 4.1–
12.2) in the storytelling group and by 5.5 mmHg (95% CI
1.4–9.5) in the comparison group; HTN medication ad-
herence increased in the storytelling group and declined
in the comparison group. Building on the findings of this
feasibility trial, we proposed a full-scale cluster random-
ized controlled clinical trial to evaluate the implementa-
tion and effectiveness of two multi-faceted community
and clinic-based strategies on the control of elevated
blood pressure among adult men and women in
Vietnam.
Methods
Intervention approaches and implementation framework
Patient-centered interventions
Interventions focused on how patients may reduce their
risk of CVD through lifestyle changes including weight
control, increased physical activity, tobacco avoidance,
moderate intake of salt and alcohol, and adherence to
prescribed medications [17–19].
Home blood pressure self-monitoring
Home self-blood pressure monitoring enhances patient
self-management and empowerment. Compared with
office-based readings, home blood pressure monitors
may provide better prognostic information about CVD
outcomes [20]. Several studies have documented the
value of home blood pressure monitoring in improving
HTN control [21–23] and increased patient adherence
to blood pressure lowering medications [24, 25].
Community health workers
Community health workers (CHWs) are “natural
helpers” who serve as health advocates for their local
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communities [9]. A CHW may serve as an educator
and problem-solver and provide a valuable linkage to
community resources and health promotion activities
[10, 26]. Recent studies have documented the positive
role of CHWs in improving HTN control [11, 12, 27],
and CHWs are present in our partnering rural clinics
and were an integral part of our previous work [14–
16].
Intervention model
Wagner’s original Chronic Care Model [28], subse-
quently expanded [29], provides a conceptual foundation
for addressing multi-level barriers to HTN control
(Fig. 1). Although we do not have the capacity in rural
Vietnam to implement all components of this model, it
still provides a systematic framework for organizing our
multi-level intervention. This model has been success-
fully used for HTN management [12, 30, 31], and we
have adapted it for the rural Vietnamese setting to guide
our intervention strategy. Our intervention components
map directly to the Chronic Care Model in the domains
of patient self-management support (storytelling, home
blood pressure monitoring), clinician decision support
(medication management as part of the Vietnam Na-
tional HTN Program), delivery system design (standard-
ized blood pressure measurement), clinical information
systems (tracking software available through the
Vietnam National HTN Program), health care
organization (leadership buy-in), and community re-
sources (CHWs).
Implementation framework
While we considered several implementation frame-
works [32–34], we chose the Promoting Action on
Research Implementation in Health Services (PARiHS)
model because we will be implementing a multi-level
model in a de-centralized system with semi-
autonomous clinical delivery systems. PARiHS relies
on three interactive elements: evidence, context, and
facilitation [35–37], which play key roles in our
intervention.
Our specific aims are as follows:
1. Conduct a pre-implementation local needs assess-
ment and formative planning in 16 partnering com-
munes in Hung Yen province, Vietnam, leading to a
context-specific protocol for implementing the
Vietnam National Hypertension Program in both
intervention and comparison communities and pro-
posed enhancements (expanded CHW services,
home blood pressure self-monitoring, and storytell-
ing in the 8 intervention communities only).
2. Implement a cluster randomized controlled trial
(RCT) (Type I Hybrid Implementation Design) of
16 communities and 680 patients with HTN
randomized to either an intervention group
(Vietnam National Hypertension Program plus 3
trial enhancements) or a comparison group
(Vietnam National Hypertension Program alone).
3. Compare the effectiveness and implementation
success of the two approaches using data from
multiple sources at multiple points in time,
Fig. 1 The adapted Chronic Care Model
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including blood pressure measurements, patient
surveys, and interviews with clinic personnel and
clinicians. Our main study hypothesis is as follows:
at 12 months post-randomization, participants in
the intervention group will have a greater mean re-
duction in their levels of blood pressure than those
in the comparison group.
Study setting
The study will be conducted in the Red River Delta Re-
gion in northern Vietnam. In this region, communes
(communities) in Hung Yen province were selected
based on their general representativeness. Hung Yen
province has a population of approximately 1.3 million,
organized into 10 districts and 161 communes. In
Vietnam, the health system is organized into four levels,
namely central, provincial, district hospital, and the low-
est level, which includes the community health centers
(CHCs) that are responsible for providing primary health
care and outpatient services. Patients with HTN are typ-
ically treated and managed at the district health centers
unless they need to be referred for a higher level of care.
Needs assessment study
During the first 6 months of funding, we will conduct a
qualitative study—needs assessment survey at participat-
ing study sites. We recognize the multi-level ecological
context of our intervention with layers of influence on
health status, health behaviors, and behavioral changes
beyond the individual. These include (1) community (in-
dividuals and families), (2) participating organizations,
(3) socio-cultural environment, (4) physical built envir-
onment, and (5) the broader policy environment.
The needs assessment survey will be based on the tri-
angulation of multiple data sources, including databases
documenting the prevalence and control of HTN in the
study communes, and semi-structured interviews with
clinicians, clinic staff, CHWs, and community members.
The structured interviews will ascertain perceptions of
clinicians and clinic leadership about the evidence for
treating HTN (evidence), strengths and limitations of
the current environment for implementing new tools for
HTN control proposed as part of our intervention (con-
text), and specific approaches needed to overcome bar-
riers to blood pressure control (facilitation).
As part of the needs assessment survey, we will per-
form 21 full semi-structured, individual interviews in a
randomly selected subset of three communities from the
intervention sites and three communities from the com-
parison sites. This will consist of semi-structured inter-
views with clinicians, nurses, and leadership at the
health centers and interviews with patients with uncon-
trolled HTN. We will work closely with the Department
of Health in Hung Yen province to identify stakeholders
who understand and are involved in HTN management
in the community and physicians who have managed
HTN patients at the provincial and district hospitals to
participate in the study. Patients with uncontrolled HTN
will be referred by their physicians at the local hospitals.
Brief structured qualitative assessments will be con-
ducted at all remaining sites via focus group discussions
(FGDs). We will conduct 9 FGDs at 3 study
communities.
These interviews will be repeated on three occasions
in study years 1, 3, and 5. The second and third rounds
of interviews will employ a similar design to the first
round, and there several additional questions will assess
the progress of the study implementation. We anticipate
that after intervention implementation, the gaps in HTN
management found in the needs assessment study will
be narrowed to a greater degree in the intervention
group. Information on intervention acceptability, appro-
priateness, feasibility, and fidelity will be collected as
well.
A cluster randomized controlled trial (Type I Hybrid
Implementation Design)
A full-scale cluster RCT will be conducted in Hung Yen
province, Vietnam. Sixteen communities (communes)
and 680 patients with HTN will be randomized to either
an intervention (Vietnam National Hypertension Pro-
gram plus 3 trial enhancements) or a comparison group
(Vietnam National Hypertension Program alone) (Fig. 2).
The schedule of enrolment, interventions, and assess-
ments is presented in Fig. 3.
Study sites
A total of 16 eligible communes in 4 districts in Hung
Yen province will be randomly assigned to either the
intervention (n = 8) or the comparison group (n = 8).
Each of the selected communes satisfies the following
criteria: (1) have a CHC with a medical doctor, (2) are
not currently participating in other studies for HTN
control, and (3) have a minimum geographic separation
of 12 km (7miles) from all other study communities to
minimize possible contamination. Eligible and consent-
ing trial participants with uncontrolled HTN (n = 680;
approximately 43 patients per commune) will be
assigned to intervention versus comparison status based
on the community in which they reside.
Participant eligibility
To be enrolled in our pilot study, consenting adult men
and women must fulfill each of the following criteria: (1)
be a resident of the selected commune and have no
plans for moving during the next 12 months after trial
enrollment; (2) be aged 25 years or older, a cutoff which
is commonly used in population-based surveillance
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studies of HTN in Vietnam [6, 8]; (3) have a diagnosis of
uncontrolled HTN according to the 8th Joint National
Commission of High Blood Pressure (JNC 8) [38]; (4)
not be cognitively impaired (as assessed by study physi-
cians); (5) not be a “story teller” used to develop the
intervention; (6) not be a family member of another par-
ticipant in the study; and (7) not pregnant.
In addition, those diagnosed with elevated BP for the
first time will be invited for re-measurement of their BP
over the next 2 weeks (minimum of 1 week apart) after
their initial CHC visit. If their average BP remains ele-
vated, these persons will be invited to participate in the
trial. Trained study nurses at study sites will obtain in-
formed consent from eligible patients. Both newly diag-
nosed and prevalent patients with HTN (treated or
otherwise) will be enrolled. If they are not treated at the
time of trial enrollment, they will be referred to their
district health centers for a follow-up exam and initi-
ation of treatment, which will be covered by public
health insurance. Members of the study team will work
closely with doctors at the district health centers to fol-
low up these patients.
Study recruitment and randomization
Sixteen communities will be randomly assigned to either
the intervention or the comparison condition stratified
by districts using the STATA program. In each district,
2 communes will be randomly assigned to the interven-
tion group and 2 communes will be randomly assigned
to the comparison group. Patients will be recruited from
the community setting. Screening events to identify pa-
tients satisfying our study criteria will be conducted at
local CHCs. A second screening visit will be scheduled
for eligible patients with elevated blood pressure (BP)
values (systolic BP ≥ 140 mmHg, or diastolic BP ≥ 90
mmHg) 2 weeks later, at which time their BP will be re-
measured and written informed consent will be ob-
tained. Individuals who are found to have elevated BP at
the time of clinic screening and are not willing to par-
ticipate in the study will be referred for usual care at
local district health centers.
The recruitment will rely on CHWs embedded in both
the clinic and the community, which will provide cred-
ibility and trust. The CHWs and study nurses will offer
BP screenings at their CHCs. With this approach, our
recruitment goals will achieve in the allotted time.
After enrollment, a reminder letter will be sent to all
participants before each of the follow-up visits. One
week before the scheduled follow-up visit, local staff will
contact study participants by phone. Because the com-
munes are small, it is easy to visit participant’s homes. If
patients miss their follow-up visit, local staff will contact
them by phone to remind them to come into the CHC
or visit their homes to measure their BP, if necessary.
Patients can withdraw from the study at any time during
the study period. If patients move out from their com-
munes permanently, they will be considered as dropping
out from the study.
Intervention condition and delivery
Detailed interventions and delivery methods are de-
scribed in Table 1.
Vietnam National HTN Program (intervention and
comparison groups) The Vietnam National HTN Pro-
gram is part of a comprehensive Vietnam National Strat-
egy on Prevention and Control of Non-Communicable
Diseases [39]. This multi-arm national strategy was
Fig. 2 Study flow
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Fig. 3 The schedule of enrolment, interventions, and assessments
Table 1 Intervention components by study group
Intervention enhancements Intervention Comparison
1 Vietnam National HTN Program




2 Expanded community health worker services
Support and strengthen their role in motivating patients through
lifestyle changes and antihypertensive medication adherence
Yes No
3 Home self-blood pressure monitoring
Free home BP monitors
Record BP in a pre-tested log and share with their physicians and
CHWs
Yes No, will be given BP monitor and BP log after the study
has ended
4 Storytelling intervention
4 DVDs with stories from Stars: baseline and 3, 6, and 9 months
Learn More Module
Yes No (only 2 DVDs with Learn More Module), will be given
4 storytelling DVDs after the study has ended
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approved by the Prime Minister in 2015, merging several
national programs into a cohesive, integrated approach.
The Vietnam National HTN Program was authorized in
2008 including various training sessions about HTN pre-
vention and management for physicians and nurses, and
a comprehensive set of patient education materials writ-
ten in a culturally and literacy-appropriate manner.
Multi-media community service announcements have
been prepared for local television and radio stations and
newspapers, and will be implemented in both study
groups. There will be a series of training sessions for
health care providers which will be carried out at local
district or provincial health departments in collaboration
with the Vietnam Ministry of Health.
Expanded community health worker services
(intervention group only) CHWs are currently embed-
ded in the clinical system for each of our partnering
CHCs and across the nation. A critical enhancement for
the intervention group will be to support and strengthen
their role in activating patients to more actively manage
their HTN through lifestyle changes and adherence to
prescribed antihypertensive medication. CHWs will be
trained in motivational interviewing and structured
problem-solving. This behavioral change counseling ap-
proach facilitates improvements in diet, exercise, adher-
ence to medication regimens, tobacco use, and overall
engagement in one’s care [40]. CHWs without advanced
health care training can be safely trained in this dynamic
approach to facilitate health behavior change with
proven effectiveness [41, 42].
CHWs will also be taught simple techniques to help
patients set goals for a number of lifestyle changes, in-
cluding salt and alcohol reduction, smoking cessation,
increased physical activity, and enhanced medication ad-
herence; they will also develop problem-solving strat-
egies to achieve these goals. CHWs will be taught how
to work with patients to (1) engender engagement and
commitment by self-identifying goals that are meaning-
ful and consistent with their personal lives and family
context; (2) promote feasibility by identifying a limited
set of goals and small, attainable steps; (3) provide edu-
cational resources; (4) establish a structure for account-
ability and support through regular review; and (5) link
goal attainment to changes in self BP monitoring for
reinforcement. These techniques were successfully used
in our pilot work [15].
As in our pilot work, CHWs will be taught how to use
the storytelling intervention (below) to start conversa-
tions with their patients with elevated BP values. After
each DVD of the storytelling intervention, CHWs will
meet with the patient to review the material, elicit pos-
sible barriers to lifestyle changes and medication treat-
ment, and identify strategies to overcome recognized
barriers. CHWs will make bi-weekly patient home visits
(1 h) to resolve difficulties related to viewing the DVDs,
and they will keep detailed logs of their patient interac-
tions to help provide a qualitative sense of intervention
effectiveness and suggest approaches for improvement.
There will be a series of training sessions for CHWs,
which will be delivered locally in the collaboration with
the Vietnam Ministry of Health.
Home self-blood pressure monitoring (intervention
group only) Home BP self-monitoring is the second en-
hancement for the intervention group. The intervention
group will receive free home BP measurement devices at
the time of trial enrollment at their CHCs whereas pa-
tients in the comparison group will receive home BP
monitors and a BP log after the study has ended. After
obtaining informed consent, a trained CHW will instruct
patients on how to use the BP measurement devices at
home and how to record their BP readings in the BP log
previously developed and implemented by the study
team. Readings will initially be taken in the morning
after arising and again at night before going to sleep. Pa-
tients will be advised about reading variability, cautioned
about overreacting to a single elevated BP value, and
given specific protocols for when to contact a health
care provider should the need arise. Patients are rou-
tinely given a portable copy of their medical record with
instructions to bring it to future clinic appointments.
Storytelling intervention (intervention group only)
Our team has previously designed, implemented, and
pilot tested such an intervention for improving HTN
control in Vietnam [14–16]. The patient narratives in-
cluded in the intervention materials include first-hand
accounts from patients in their journey to gain control
of their HTN, and the stories are complemented by add-
itional formal information about HTN control. This
Learn-More section will be built on the stakeholders’
opinions gathered via interviews and national experts in
HTN control. For our newly proposed work, we will
supplement this previously developed material with new
patient stories to represent our expanded community
base. We will develop four storytelling DVDs, the first to
be delivered to intervention patients at the time of trial
enrollment, with viewing in the clinic, followed by in-
stallments at 3, 6, and 9 months to be viewed at home.
All intervention participants will be provided with a
DVD player and instructed in how to navigate the menu
structure of the DVDs at enrolment. After each install-
ment, we will administer a post-media interview to as-
certain the frequency and duration of viewing, change in
behavioral intentions, and overall satisfaction with the
intervention; these data will be used for the mediation
analysis to describe implementation and mechanisms of
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intervention effectiveness. At 3 and 6 months after trial
enrollment, a second and third installment of the DVDs
will be delivered at the patient’s local CHC for home
viewing by patients assigned to the storytelling interven-
tion group. At 9 months after trial enrollment, the
fourth DVD will be delivered at participant’s home by
the CHWs.
We will develop 2 short DVDs with Learn-More sec-
tion only for the comparison group. Patients in the com-
parison group will receive a DVD player and the first
DVD at trial enrollment and the second DVD at month
6 at their local CHC.
For both groups, after viewing the DVDs, a follow-up
visit will be scheduled for a “post-media” interview and
re-measurement of patient’s BP by a trained CHW.
Sample size
Sample size calculations are based on our primary trial
hypothesis with between-group differences in over-time
changes in systolic BP as the principal trial outcome.
Our previous pilot work in rural Vietnam suggests that
it is feasible to achieve an over-time improvement of 8
mmHg in systolic BP with a standard deviation of 18
mmHg. Analysis of pilot data revealed an intra-class cor-
relation of 0.011 for the clustering of participants in
communes for change in systolic BP. We first performed
unadjusted sample size calculations that did not account
for clustering of individuals within study site and did not
inflate for possible losses to follow-up. For these calcula-
tions, we set alpha error at 0.05 and examined a range of
power from 0.8 to 0.9 based on the two-sided t test with
a common standard deviation of 18, assuming that the
mean improvement in systolic BP is 8 mmHg for pa-
tients in the intervention condition and 3mmHg for
those in the comparison condition.
Next, we adjusted these first-pass sample size calcula-
tions to account for the clustering of participants. Ac-
cording to Donner: Nadjusted = Nundjusted(1 + (m − 1)r), in
which Nadjusted is the total sample size adjusted for clus-
tering, Nundjusted is the unadjusted total sample size, m is
the unadjusted average cluster size (average number of
patients/community), and r is the intra-class correlation
(ICC) [43]. Finally, we inflated the resulting sample size
by approximately 10% to account for potential losses to
further follow-up. It is important to note that the
planned analyses for this study will draw upon the power
of longitudinal measurement, which will be more power-
ful than the above-presented estimates [14]. Data to in-
form these calculations were based on recently
published work and are summarized in Table 2.
In addition to the main analyses described above,
we also anticipate adequate power for the planned
mediation analysis. For the mediation analysis, simula-
tion studies revealed that a sample size of 500 is ad-
equate to detect pathways with small standardized
effect sizes (as low as 0.14) at 80% power with
methods described above [44].
Data collection
Data sources include the following: (1) standardized BP
and anthropometric measurements at baseline and at 3,
6, and 12months after trial enrollment; (2) quantitative
participant surveys at baseline and at 3, 6, and 12
months after enrollment; (3) post-media interviews after
each installment of the storytelling intervention for the
intervention group; (5) medical record review; (6) imple-
mentation data gathered by the research coordinator
and CHWs that will inform progress toward specific
study milestones; and (7) semi-structured interviews for
qualitative data.
Blood pressure and anthropometric measurement As
previously described, certified study nurses will be
trained to measure BP according to a standardized
protocol approved by the World Health Organization
[45]. We used this protocol in our previous randomized
trial of storytelling in Vietnam. This protocol was writ-
ten for use with the OmROn HEM-8712 automated BP
monitor, with special attention to assessment and main-
tenance of the instrument’s accuracy and training/certifi-
cation of research assistants. Using a proper cuff size,
measurements are taken after sitting quietly for 5 min,
with the arm supported on a flat surface, with the upper
arm at heart level. Three measurements are separated by
at least 1 min, and values from the last two measure-
ments will be averaged. Height and weight will be
Table 2 Sample size calculations
Power Sample size
Unadjusted Cluster-adjusted1 Cluster-adjusted and retention inflated2
0.80 410 522 573
0.85 468 614 674
0.90 548 549 823
Sample size calculations assume an improvement in systolic blood pressure of 8 mmHg in the intervention group and 3mmHg in the comparison group for a
differential, over-time improvement of 5 mmHg. Alpha error is set at 0.05
1According to approach described by Donner and setting intra-class correlation coefficient at 0.011 based on pilot data
2Final calculations are inflated by approximately 10% to account for potential loss to follow-up
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measured in the absence of shoes and heavy clothing
while waist and hip sizes will be measured by placing the
tape horizontally around the smallest part of the waist
and the widest portion of the hips, respectively.
Participant surveys All survey items will be taken from
validated instruments, with scales or sub-scales left in-
tact to preserve psychometric properties [46]. The survey
will be implemented in a computer-assisted format and
pilot tested for acceptability. The target duration time
for the final survey will be less than 1 h. We will collect
information on patient’s level of education, occupation,
and economic circumstances using the WHO STEPs
protocol [47, 48]. STEPs will also be used to collect data
on CVD risk factors including tobacco use, alcohol con-
sumption, salt intake, and physical activity. Adherence to
anti-HTN medications will be measured using standard-
ized forms previously developed by Duke University
[49]. The Medication Adherence Self-efficacy Scale
(MASES) instrument [50, 51] will measure self-efficacy
in HTN management. Quality of life will be measured
by the short form 12 questionnaire health survey (SF-12)
[52]. All the survey measures previously existed in Viet-
namese or have been translated and tested by our team
as part of our previous work [15] with the exception of
the adherence to anti-HTN medications, which will be
translated following the set of best practices developed
by the US Census Bureau [53]. Translation will be ac-
complished by a translation team led by study PIs, with
multiple versions prepared in parallel followed by team
meetings to reconcile possible differences. This approach
has been shown to be superior to the simple “back-
translation approach” in which translation by a single in-
dividual is translated back into the source language for
review of accuracy [54]. Translation will include cogni-
tive interviews with five participants drawn from the
local community. Cognitive testing will identify con-
structs specific to the Vietnamese language and culture
so that appropriate adjustments may be made to ensure
cross-cultural equivalence [55]. Several cycles of revision
will be accomplished at full translation committee meet-
ings conducted in person and by Internet video link.
Post-DVD viewing interviews for intervention partici-
pants will be based on protocols previously developed by
our team. The post-DVD viewing interviews using a
structured questionnaire will collect self-reported en-
gagement with the DVDs, including total viewing mi-
nutes, specific segments that were viewed, and whether
the DVD was shared with family or friends. “Transporta-
tion” is a validated concept measuring absorption into
the video story that has been linked to intervention ef-
fectiveness and is measured by a validated scale [56, 57].
Participants will be asked to elaborate on what moti-
vated/hindered their intervention engagement.
Data management
Data will be stored on a Health Insurance Portability
and Accountability Act (HIPAA)-compliant secure ser-
ver with daily backup at the Health Strategy and Policy
Institute and managed by the study data manager who is
familiar with the REDCap database. This person will
work closely with the PIs and experts at University of
Massachusetts Medical School to make sure that the
data are managed properly.
Study outcomes
Primary outcomes Change in patient’s systolic BP levels
over the 1-year follow-up period is the primary trial out-
come. Registered nurses will be trained and certified to
measure patient’s BP according to a protocol approved
by the World Health Organization [45]. Three measure-
ments of BP will be carried out, and values from the last
two measurements will be averaged with the first read-
ing ignored.
Secondary outcomes Changes in diastolic BP, risk fac-
tors for CVD, medication adherence, self-efficacy, quality
of life, cost, and implementation outcomes are secondary
outcomes of this study. The WHO STEPs survey, which
has been used to investigate the epidemiology of HTN
in the Vietnamese language [48], will be used to collect
data on several risk factors for CVD. Costs include the
following: (1) program costs, which consist of costs to
develop the intervention and implementation costs in-
curred at the district and community levels, and (2) pa-
tient costs such as drugs, diagnostic procedures, time
lost, health center visits, and consultation fees.
Implementation outcomes including acceptability, ap-
propriateness, adaptation, feasibility, fidelity, and sustain-
ability will be collected via semi-structured interviews
and focus group discussions among stakeholders and pa-
tient interviews, and post-DVD viewing surveys at
follow-up visits. The implementation data and barriers
to study milestones achievement gathered by the re-
search team will inform strategies to overcome barriers
and progress toward specific study milestones.
Data analysis plan
Qualitative analysis In particular, we will use a well-
accepted type of qualitative analyses often described as
thematic analysis. Thematic analysis will be applied to
the narratives obtained via Story Development Groups
as well as from individual interviews from Video Stars
and will proceed as follows: (1) entering transcripts into
NVivo (qualitative software), (2) performing initial
in vivo coding to separate the full story into initial story
units, (3) tagging story units with codes from pre-
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existing codebook as well as any additional themes that
emerge, and (4) grouping related codes based on broader
themes connecting the experiences of participants to key
concepts from our conceptual frameworks, which will be
explored in the intervention. Thus, our approach to the-
matic analysis will include open coding, followed by con-
cept building, and the development of themes/categories
[58, 59]. Three members of the team will code these
data—using the Link and Phelan framework [60] as a
guide. Rich data will be gathered from multiple sources
to drive the qualitative analyses. Interview notes and re-
cordings from the Story Development Groups and inter-
views of Video Stars will be linked by a code, and
recordings will be destroyed after verification of notes.
For needs assessment study, we will also utilize the-
matic qualitative analysis utilizing the qualitative soft-
ware platform NVivo to objectively identify and catalog
the perceptions expressed in these interviews. The inter-
views will be analyzed utilizing a thematic analysis ap-
proach to identify central themes as they appear in
interviews. The identified overarching themes will serve
as a baseline to build upon the packaged narratives to be
presented visually in the DVDs.
Detailed field notes and codebooks will be maintained.
Qualitative data analysis software will support the coding
activities for the thematic analysis process above and will
allow for inter-rater reliability testing among multiple
coders, who will achieve at least a 90% agreement rate.
Quantitative analysis We will begin the statistical ana-
lysis by examining univariate statistics, including mea-
sures of central tendency and dispersion. We will
carefully document the trial recruitment and retention
process with a CONSORT diagram [61, 62]. In accord-
ance with best practice, differences in baseline character-
istics of the intervention and comparison groups will be
established based on standardized differences, rather
than on tests of statistical significance [63, 64].
All primary hypothesis testing will be performed on an
intent-to-treat basis and will be two-sided with alpha
error will be set at 0.05. For the main study hypothesis,
the continuous outcomes will be systolic (H1) and dia-
stolic (H2) BP. We will use a generalized linear mixed
model adjusting for important potential covariate imbal-
ances between the two primary study comparison
groups. Since we will collect longitudinal data with re-
peated observations nested within participant, and par-
ticipants nested within community, many statistical
analyses will be based on a generalized linear mixed
model with Restricted Maximum Likelihood (REML) es-
timation that accounts for the complex data structure
through random effects response [65–68].
We will use mediation analysis to disentangle the mul-
tiple mechanisms which may be associated with the
effectiveness of our multi-level intervention. Patient-
level mediators of intervention effectiveness include the
following: (1) intervention engagement (measured by
number of CHW sessions completed and time spent in
the sessions, types of goals set and corresponding action
plans, BP self-monitoring, and engagement with the
storytelling intervention), (2) medication adherence, (3)
adherence to heart-healthy lifestyle recommendations,
and (4) patient activation. Clinic-level mediators include
implementation of standardized BP measurement proto-
cols, engagement of physicians and nurses in the trial
educational programs, and fidelity of CHW intervention
delivery.
For the secondary analysis, we will examine differential
over-time changes in diastolic BP, HTN control, and
CVD risk, using statistical approaches described above
for testing the main study hypothesis. For these analyses,
a dichotomous measure of BP control will be con-
structed according to JNC-8 [38]. Overall risk of a CVD
event at 10 years will be calculated based on the Asian
Pacific Cohort equation [69]. We will examine changes
in patient’s individual risk factors for CVD (e.g., smok-
ing, physical inactivity) as well. We will carry out ex-
ploratory analyses for possible heterogeneity of
intervention effect among sub-groups of participants de-
fined by age, sex, and existing CVD.
Missing data may introduce potential bias, and the
most important defense to minimize missing data on
key factors is advanced planning [70, 71]. In our previ-
ous work, we have developed successful plans to
maximize participant retention and obtain complete data
through sound principles of data collection and quality
control [15]. Sensitivity analyses will estimate the bounds
of potential bias introduced by omissions. Under the
missing-at-random assumption, multiple imputation [72]
will generate plausible values of missing covariates while
accounting for the additional uncertainty introduced by
the omissions. All the analyses will be performed using
STATA 16.0 (Stata Corp, TX).
The economic analysis will be led by Dr. Ha, who has
expertise in evaluating the cost-effectiveness of interven-
tions to prevent CVD in Vietnam [73]. From the societal
perspective, we will analyze costs and effectiveness for
the intervention package with the proposed enhance-
ments in comparison to standard implementation of the
Vietnam National HTN Program, using approaches ap-
propriate for lower-to-middle income countries [74, 75].
Costs include the following: (1) program costs, which
consist of costs to develop the intervention and imple-
mentation costs incurred at the district and community
levels, and (2) patient costs such as medications, time
lost, health center visits, and consultation fees. We will
calculate the incremental costs of the intervention by
subtracting the average costs for the intervention group
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from the average costs for the comparison group. The
incremental cost-effectiveness ratio will be calculated as
the additional cost of the intervention divided by the
change in both systolic and diastolic BP related to the
intervention. In addition, we will calculate cost-
effectiveness ratios for BP control, by dividing the add-
itional costs of the intervention by the proportion who
achieved HTN control as a result of the intervention.
Because this is a country-specific economic analysis, all
costs will be evaluated using the Vietnamese Dong
(VND) with subsequent conversion to US dollars. We
will perform one-way sensitivity analyses related to vari-
able intervention effectiveness, variable engagement, and
trial adherence.
Timeline
The proposed study will take place over a 5-year period.
During the first 6 months of year 1, we will conduct a
needs assessment study. The next 18 months will be de-
voted for intervention enhancement development.
Training for intervention delivery will be conducted in
early year 3, right before the trial start (year 3). All data
collection activities for the trial will be completed by
mid-year 5. Year 5 will be devoted to data analysis and
manuscript writing.
Trial oversight
The trial steering committee is composed of all PIs and
study key personnel from all sites. This committee is re-
sponsible for designing and implementing the study and
recommends appropriate actions to ensure that protocol
deviations will be minimized. An independent Data
Safety Monitoring Board (DSMB) has been established
to be responsible for safeguarding the interests of study
participants, assessing the safety and efficacy of study
procedures, and monitoring the overall conduct of the
study. Communication with DSMB members will be pri-
marily through the DSMB administrator (Executive Sec-
retary—ES) and the Data Coordinating Center (DCC).
The first DSMB meeting will be held before the trial
start to review study protocol and give approval and will
meet every 6 months to reviewing data for safety and
feasibility. Additional meetings will be arranged as
needed. An interim analysis will not be performed. The
DSMB may make recommendations whether the study/
the trial will be continued or stopped. The DSMB will
also receive all Serious Adverse Event (SAE) reports and
may request additional information, as needed. In
addition, on-site monitoring visits from a qualified re-
search monitor will be scheduled quarterly until data
quality is deemed acceptable and then will be scheduled
6 monthly for the remainder of the study. The study
protocol conforms to the SPIRIT checklist
(Additional file 1).
Dissemination plan
The project will work closely with policymakers from
the Vietnam Ministry of Health to transform evidence
into a policymaking process as well as with the Vietnam
Heart Association to scale up the interventions and im-
plementation program and make them more widely
available. The process will start with a dissemination
workshop and then forums for policy dialogue with par-
ticipation of key leaders and influential people from the
Ministry of Health, policymakers, health managers, prac-
titioners, and stakeholders who are involved with the
prevention and control of non-communicable diseases in
Vietnam. The results of the trial will be published in
international peer-reviewed journals by the study team.
Discussion
We are proposing a full-scale cluster RCT to test the ef-
fectiveness of two strategies to improve HTN control for
adults residing in rural communities in Vietnam. We
will use a well-planned approach to culturally adapt
intervention enhancements that have been effective in
our feasibility trial and from other settings. If our ap-
proach is proven to be successful, it will offer policy-
makers an innovative intervention strategy to address a
well-recognized and emerging threat to public health in
Vietnam. Our approach is built on many previous “les-
sons learned” and, more importantly, is low cost and of
low burden to patients, clinicians, and health care
systems.
However, there are some potential study caveats. Due
to the nature of the study design, the trial is not blinded.
With 12months of follow-up, we are unable to assess
the long-term effects of the intervention on CVD mor-
bidity and mortality. Also, given limitations of sample
size, we are not testing each intervention component
separately. Still, mediation analysis and analysis of imple-
mentation data will help disentangle the contributions of
specific intervention components. Another potential
threat is contamination of the comparison group, if the
storytelling DVDs or home BP monitors are shared.
Thus, we specified that the distance between an inter-
vention and comparison community will be at least
10 km. Evidence of contamination will be sought
through patient interviews at the final study visit.
Patient recruitment to the trial may lag, or the inter-
vention may not be faithfully implemented. We
recognize the need for proactive monitoring and re-
sponse, and will implement previously developed proto-
cols that were successful in rural Vietnam.
Implementation data with specific milestones will pro-
vide early warnings to guide corrective action. We will
work with the NIH Scientific Officer and the structure
for coordination across studies to be funded under the
Hypertension Outcomes for T4 Research within Lower
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Middle-Income Countries (Hy-TREC) initiative for sci-
entific guidance as appropriate and to establish mean-
ingful study milestones.
The “Conquering Hypertension in Vietnam: Solutions
at Grassroots Level” will provide new evidence about the
effectiveness and implementation of the Vietnam Na-
tional HTN Program, which is being rolled out across
the nation but has not been part of a randomized trial in
its current format, and will evaluate our proposed en-
hancements to this ambitious national effort.
Trial status
The recruitment began on October 23, 2019, and will
complete on March 1, 2021.
To date, randomization has been finished and 423 pa-
tients have been recruited from 10 communes (updated
on October 18, 2020). Ninety-seven percent of patients
completed the 3-month follow-up contact (211/218 eli-
gible patients), and nearly 90% have completed the 6-
month follow-up contact (84/94 eligible patients). This
protocol is version 6, dated August 15, 2019. Any proto-
col modifications will be communicated to relevant par-
ties (e.g., IRB, trial participants) and published on
relevant channels (e.g., ClinicalTrials.gov).
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